You can buy or sell Intec Pharma and other stocks, options, ETFs, and crypto commission-free!
Intec Pharma Ltd. Ordinary Shares, also called Intec Pharma, is a clinical-stage biopharmaceutical company, which focuses on developing drugs based on its proprietary Accordion Pill platform technology. Read More Its product pipeline includes four product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients; Accordion Pill Zaleplon, which is being developed for the treatment of insomnia, including sleep induction and the improvement of sleep maintenance; an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug which induces ulcers; and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol and tetrahydrocannabinol, which is being developed for various indications including low back neuropathic pain and fibromyalgia. The company was founded by Zvi Joseph in 2000 and is headquartered in Jerusalem, Israel.
52 Week High
52 Week Low
Seeking AlphaMay 16
Intec Pharma +14% on Merck collaboration
Intec Pharma (NASDAQ:NTEC) has entered into an agreement with Merck (NYSE:MRK), to explore using the Accordion Pill (AP) platform for an undisclosed development program.
Yahoo FinanceMay 10
Fibromyalgia Treatment Market to Surpass US$ 3,607.3 Million by 2026 – Coherent Market Insights
SEATTLE, May 10, 2019 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the fibromyalgia treatment market was valued at US$ 2,778.6 million in 2018 and is projected to exhibit a CAGR of 3.3% over the forecast period (2018–2026). Key Trends and Analysis of the Fibromyalgia Treatment Market: Key players in the market are involved in robust research and development activities for the development of novel therapies indicated for treatment of fibromyalgia. Launch of novel treatments is expected to sig...
Expected Aug 14, Pre-Market